Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : Recv Dt. Time : Sample Type :
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : Report Printed : 30-Jun-2026 17:30

Out of Reference Range Result(s) Summary

Test Name Result Value Unit Reference Range
Blood Urea Nitrogen (BUN)
BUN (Blood Urea Nitrogen) 5.3 mg/dL 6 - 20
*PLEASE NOTE CHANGE IN
REFERENCE RANGE
Electrolytes
Potassium 5.66 mmol/L 3.5 - 5.1
Haemogram (CBC) LAB
Haemoglobin 10.7 g/dL 11.5 - 16.5
Mean Corpuscular Hemoglobin 22.4 pg 27 - 32
Mean Corpuscular Hb Concentration 25.5 g/dL 30 - 35
Red Cell Distribution Width (RDW) 16.1 % 11.5 - 14
Eosinophils 6.3 % 1-6
Absolute Eosinophil Count 558 Cells/cmm 20-500
Platelet Count 4,88,000 Cells/cmm 150000 - 400000
Urine Examination
Nitrites Positive mg/dL Negative
Blood Present (+) Negative
Pus Cells 3.20 /HPF 0-2.7 cells/hpf
Epithelial Cells 8.60 /HPF 0-1.1 cells/hpf
Calcium oxalate Monohydrate 2.70 /HPF 0-1.4 p/hpf
Uric Acid 2.1 /HPF 0-1.4 p/hpf
Bacteria 209.5 /HPF 0-29.5 p/hpf
Yeast 157 /HPF 0-0.7 p/hpf
25 OH Cholecalciferol (D2+D3) 16.6 ng/mL Deficient : < 20 ng/mL
Insufficient : 20 - 30 ng/mL
Sufficient : 30 - 100 ng/mL
Toxicity : > 150 ng/mL
Abnormal Result(s) Summary End
Note:
This summary highlights abnormal and trend results extracted from the report for quick reference.
It is for informational purposes only and does not require a doctor's signature.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Page 1 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Whole Blood EDTA
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:39 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Complete Blood Counts

RBC Count 4.78 millions/cmm 3.8 - 5.8

Electrical Impedance

Haemoglobin L 10.7 g/dL 11.5 - 16.5

SLS Hemoglobin Method

PCV (Haematocrit) 41.9 % 37 - 47

Pulse Light Detection Method

Mean Corpuscular Volume 87.7 fL 76 - 96

Calculated

Mean Corpuscular Hemoglobin L 22.4 pg 27 - 32

Calculated

Mean Corpuscular Hb Concentration L 25.5 g/dL 30 - 35

Calculated

Red Cell Distribution Width (RDW) H 16.1 % 11.5 - 14

Calculated

Total Leucocyte Count(TLC) 8,860 Cells/cmm 4000 - 11000

Flowcytometry

Differential Counts
Neutrophils 58.9 % 40 - 75
Flowcytometry

Lymphocytes 26.6 % 20 - 45
Flowcytometry

Monocytes 7.6 % 2 - 10
Flowcytometry

Eosinophils H 6.3 % 1-6

Flowcytometry

Basophils 0.6 % 0-1

Flowcytometry

Absolute Counts
Absolute Neutrophil Count 5219 Cells/cmm 2000-7000
Calculated

Absolute Lymphocyte Count 2357 Cells/cmm 1000-5000

Calculated

Absolute Monocyte Count 673 Cells/cmm 200-1000

Calculated

Absolute Eosinophil Count H 558 Cells/cmm 20-500

Calculated

Absolute Basophil Count 53 Cells/cmm 20-100

Calculated

Platelet Count H 4,88,000 Cells/cmm 150000 - 400000

Electrical Impedance

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Santhosh K [Link] Ravi

MD (Pathology), PDCC
(Hematopathology)
Page 2 of 14 CONSULTANT PATHOLOGIST
Verified by
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Whole Blood EDTA
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:39 Report Printed : 30-Jun-2026 17:30

Mean Platelet Volume (MPV) 10.4 fL 7.2 - 11.7

Calculated

According to ICSH guideline (international Council for Standardisation in Hematology), the differential counts should be
reported in absolute numbers.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

Santhosh K [Link] Ravi

MD (Pathology), PDCC
(Hematopathology)
Page 3 of 14 CONSULTANT PATHOLOGIST
Verified by
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Whole Blood
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ EDTA,Plasma Fluoride
:
F,Serum,Urine
30-Jun-2026 16:37 Report Printed : 30-Jun-2026 17:30
TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

ESR 19 mm after 1hr 0 - 20

Automated (Opto-electronic unit)

BIOCHEMICAL INVESTIGATIONS
Plasma Glucose - F 81 mg/dL Normal : 70 - 99
HEXOKINASE/G-6-PDH Impaired Fasting : 100 -
125
Diabetic : =>126

BUN (Blood Urea Nitrogen) L 5.3 mg/dL 6 - 20

Urease *PLEASE NOTE
CHANGE IN
REFERENCE RANGE

Uric Acid 5.00 mg/dL 2.5 - 6.2

Uricase

Creatinine 0.76 mg/dL 0.5 - 1.0

Kinetic Alkaline Picrate

Calcium 9.50 mg/dL 8.4 - 10.2

Arsenazo III

Urine Microalbumin 16.0 mg/L Normal : <30

Immunoturbidimetric

Urine Creatinine 246.54 mg/dL 16 - 327

Kinetic Alkaline Picrate *Please note change in
Reference range.

Microalbumin creatinine ratio 6.5 mg/g Normal : < 30

Calculation Microalbuminuria : 30 -
299
Macro albuminuria : =
>300

Glycated Haemoglobin Estimation

HbA1c 5.60 % Normal : <5.7
HPLC Pre diabetes : 5.7-6.4
Diabetes : >6.5

Estimated Avg Glucose (3 Mths) 114.02 mg/dL

Calculated

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] Bibi

MD Pathology,
MC-5972
Page 4 of 14 PDF HBNI Hematopathology
Verified by
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA 33 Years

Sex/Age : Female / 30 Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Whole Blood
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ EDTA,Plasma Fluoride
:
F,Serum,Urine
30-Jun-2026 16:37 Report Printed : 30-Jun-2026 17:30
Interpretation :
HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.
Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.
Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.
Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.
In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.
The A1c target should be individualized based on numerous factors, such as age, life expectancy,comorbid conditions, duration of diabetes,
risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] Bibi

MD Pathology,
MC-5972
Page 5 of 14 PDF HBNI Hematopathology
Verified by
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 15:29 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

LIVER FUNCTION TEST

Bilirubin Total 0.30 mg/dL 0.2 - 1.2

Diazonium Salt

Bilirubin Direct 0.14 mg/dL 0 - 0.5

DIAZO REACTION

Bilirubin Indirect 0.16 mg/dL 0.1 - 1

Calculated

ALT (SGPT) 14.00 U/L 0 - 34

NADH (Without P-5-P)

AST (SGOT) 20.00 U/L 11 - 34

NADH (Without P-5-P)

Alkaline Phosphatase 75.00 U/L 40-150

Para-Nitrophenyl Phosphate

Gamma Glutamyl Transferase 12.00 U/L 0 - 38

L-Gamma-glutamyl-3-carboxy-4-nitroanilide
Substrate

Proteins (Total) 7.76 g/dL 6.4 - 8.3

Biuret

Albumin 4.60 g/dL 3.5-5.0

Bromo Cresol Green

Globulin 3.16 g/dL 2.0 - 3.5

Calculated

A/G Ratio 1.5 1.0 - 2.0

Calculated

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] R
Consultant Biochemist MC-5972
Verified by Page 6 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 15:29 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Lipid Profile

Cholesterol 156 mg/dL <200 - Desirable

Enzymatic
200 - 239 - Borderline High
> 240 - High
"NCEP Guidelines ATP III".
Triglyceride 82 mg/dL < 150 - Normal 150 - 199 -
Glycerol Phosphate Oxidase
Borderline 200 - 499 - High
> 500 - Very High "NCEP
Guidelines ATP III".
HDL Cholesterol 54 mg/dL < 40 - Low Level
Accelerator Selective Detergent
40 - 60 - Average Level
> 60 - High Level
NCEP Guidelines ATP III.
LDL Cholesterol 89.42 mg/dL 0 - 100
Calculated

VLDL 16.40 mg/dL <30

Calculated

Non-HDL Cholesterol 102 < 130 Optimal

Calculated
130-159 Near Optimal
160-189 Borderline high
190-219-High
>or = 220- Very high
LDL/HDL Ratio 1.66
Calculated

Chol/HDL 2.89 < 3.5 – Low risk

Calculated
3.5 – 5.0 - Normal risk
> 5.0 - High risk

Interpretation
LDL Cholesterol:
LDL-C estimated using the modified Sampson (NIH) equation,preferred over Direct & Friedewald methods as per
ACC/AHA 2026 guidelines". TGL >800, direct LDL is preferred.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] R
Consultant Biochemist MC-5972
Verified by Page 7 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:15 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

Antibody to HBs 1.890 mIU/mL Less than 10 mIU/ml :No

CMIA Immunity More than 10
mIU/ml : Acquired
immunity
Interpretation :
Based on the World Health Organization recommendation, an Anti-HBs concentration >= 10 mIU/mL is regarded as being
protective against Hepatitis B viral infection.
It is used for the quantitative determination of antibody to Hepatitis B surface antigen(anti-HBs) in human serum and plasma.
Anti-HBs assays are often used to monitor thesuccess of Hepatitis B vaccination. The presence of anti-HBs has been shown to
beimportant in protection against Hepatitis B virus (HBV) infection.
Assays for anti-HBs are also used to monitor the convalescence and recovery of Hepatitis B infected individuals.
Note:
• If the Anti-HBs results are inconsistent with clinical evidence, additional testing is suggested to
confirm the result.
• For diagnostic purposes, results should be used in conjunction with patient history and other
hepatitis markers for diagnosis of acute, chronic, or recovered infection.

BIOCHEMICAL INVESTIGATIONS
Free T3 2.36 pg/mL 1.58 - 3.91
CMIA

Free T4 1.18 ng/dL 0.70 - 1.48

CMIA

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr K Vinodini
MBBS., M.D(Micro)
MC-5972
Verified by Page 8 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:15 Report Printed : 30-Jun-2026 17:30

BIOCHEMICAL INVESTIGATIONS
TSH 1.02 µIU/mL 0.35 - 4.94
CMIA PREGNANCY:
First trimester : 0.1 - 2.5
Second trimester : 0.2 -
3.0
Third trimester : 0.3 - 3.0

INTERPRETATIONS

• Circulating TSH measurement has been used for screening for euthyroidism, screening and diagnosis for
hyperthyroidism & hypothyroidism. Suppressed TSH (<0.01 µIU/mL) suggests a diagnosis of hyperthyroidism
and elevated concentration (>7 µIU/mL) suggest hypothyroidism. TSH levels may be affected by acute illness
and several medications including dopamine and glucocorticoids. Decreased (low or undetectable) in Graves
disease. Increased in TSH secreting pituitary adenoma (secondary hyperthyroidism), PRTH and in
hypothalamic disease thyrotropin (tertiary hyperthyroidism). Elevated in hypothyroidism (along with decreased
T4) except for pituitary & hypothalamic disease.
• Mild to modest elevations in patient with normal T3 & T4 levels indicates impaired thyroid hormone reserves &
incipent hypothyroidism (subclinical hypothyroidism).
• Mild to modest decrease with normal T3 & T4 indicates subclinical hyperthyroidism.
• Degree of TSH suppression does not reflect the severity of hyperthyroidism, therefore, measurement of free
thyroid hormone levels is required in patient with a supressed TSH level.
CAUTIONS
Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.
Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or
imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the
assay reagents to produce unreliable results.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr K Vinodini
MBBS., M.D(Micro)
MC-5972
Verified by Page 9 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:15 Report Printed : 30-Jun-2026 17:30

BIOCHEMICAL INVESTIGATIONS

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO Dr K Vinodini
MBBS., M.D(Micro)
MC-5972
Verified by Page 10 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:37 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Amylase 66.0 U/L 28 - 100 U/L

Ethylidene Blocked-pNPG7
Pl note change in BRI.
Lipase 28.00 U/L < 60 U/L
Colorimetric, Quinone Dye
Pl Note Change in BRI

Electrolytes
Sodium 144.00 mmol/L 136 - 145
ISE, Indirect

Potassium H 5.66 mmol/L 3.5 - 5.1

ISE, Indirect

Chloride 107.00 mmol/L 98 - 107

ISE, Indirect

Bi Carbonate 27.00 mmol/L 22 - 29

Enzymatic

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] R
Consultant Biochemist
Verified by Page 11 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Serum
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:15 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

VITAMIN D

25 OH Cholecalciferol (D2+D3) L 16.6 ng/mL Deficient : < 20 ng/mL

CMIA Insufficient : 20 - 30
ng/mL
Sufficient : 30 - 100
ng/mL
Toxicity : > 150 ng/mL

25-OH-VitD plays a primary role in the maintenance of calcium homeostasis. It promotes intestinal calcium absorption and, in concert with PTH, skeletal calcium
deposition, or less commonly, calcium mobilization. Modest 25-OH-VitD deficiency is common; in institutionalised elderly, its prevalence may be >50%. Although much
less common, severe deficiency is not rare either. Reasons for suboptimal 25-OH-VitD levels include lack of sunshine exposure, a particular problem in Northern latitudes
during winter; inadequate intake; malabsorption (e.g, due to Celiac disease); depressed hepatic vitamin D 25-hydroxylase activity, secondary to advanced liver disease;
and enzyme-inducing drugs, in particular many antiepileptic drugs, including phenytoin, phenobarbital, and carbamazepine, that increase 25-OH-VitD metabolism.
Hypervitaminosis D is rare, and is only seen after prolonged exposure to extremely high doses of vitamin D. When it occurs, it can result in severe hypercalcemia and
hyperphosphatemia.

INTERPRETATION
Levels <10 ng/mL may be associated with more severe abnormalities and can lead to inadequate mineralization of newly formed osteoid, resulting in rickets in children
and osteomalacia in adults. In these individuals, serum calcium levels may be marginally low, and parathyroid hormone (PTH) and serum alkaline phosphatase are usually
elevated. Definitive diagnosis rests on the typical radiographic findings or bone biopsy/histomorphometry.
Patients who present with hypercalcemia, hyperphosphatemia, and low PTH may suffer either from ectopic, unregulated conversion of 25-OH-VitD to 1,25 (OH)2-VitD, as
can occur in granulomatous diseases, particularly sarcoidosis, or from nutritionally-induced hypervitaminosis D. Serum 1,25 (OH)2-VitD levels will be high in both groups,
but only patients with hypervitaminosis D will have serum 25-OH-VitD concentrations of >80 ng/mL, typically >150 ng/mL.
Patients with CKD have an exceptionally high rate of severe vitamin D deficiency that is further exacerbated by the reduced ability to convert 25-OH- VitD into the active
form, 1,25 (OH)2-VitD. Emerging evidence also suggests that the progression of CKD & many of the cardiovascular complications may be linked to hypovitaminosis D.
Approximately half of Stage 2 and 3 CKD patients are nutritional vitamin D deficient (25-OH-VitD, less than 30 ng/mL), and this deficiency is more common among stage 4
CKD patients. Additionally, calcitriol (1,25 (OH)2-VitD) levels are also overtly low (less than 22 pg/mL) in CKD patients. Similarly, vast majority of dialysis patients are found
to be deficient in nutritional vitamin D and have low calcitriol levels. Recent data suggest an elevated PTH is a poor indicator of deficiencies of nutritional vitamin D and
calcitriol in CKD [Link] Long term use of anticonvulsant medications may result in vitamin D deficiency that could lead to bone disease; the anticonvulsants
most implicated are phenytoin, phenobarbital, carbamazepine, and valproic acid.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] R
Consultant Biochemist MC-5972
Verified by Page 12 of 14
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Urine
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:41 Report Printed : 30-Jun-2026 17:30

TEST RESULTS UNIT BIOLOGICAL REF RANGE TEST REMARK

Urine Routine Examination
Physical Examination
Appearance LIGHT TURBID Clear
Automated - Light Scattering

Colour Yellow Straw to Yellow

Automated - Light Scattering

Reaction (pH) 5.0 5-9

Indicator

Specific gravity 1.016 1.000-1.030

Refractive Index

Chemical Examination
Protein Negative mg/dL Negative
Reflectance Photometry (Protein Error of
Principle indicator)

Glucose Negative mg/dL Negative

Reflectance Photometry - Glucose Oxidase &
Peroxidase

Bile Pigments Negative mg/dL Negative

Fouchet`s test

Urobilinogen Not increased mg/dL 0-2 mg/dl

Coupling of Urobilinogen with stabilized
Diazonium Salt

Ketones Negative mg/dL Negative

Reflectance Photometry - Sodium Nitroprusside

Nitrites Positive mg/dL Negative

Griess Reaction

Blood Present (+) Negative

Peroxidase

Leucocyte Negative Leu/µL

Granulocyte esterase

Microscopic Examination
Red Blood Cells 0 /HPF 0-2.3 cells/hpf
Phase Contrast Microscopy (Sedimentation
based with AIEM)

Pus Cells H 3.20 /HPF 0-2.7 cells/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Epithelial Cells H 8.60 /HPF 0-1.1 cells/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Hyaline Casts 0 /HPF 0-0.5 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] Bibi

MD Pathology,
MC-5972
Page 13 of 14 PDF HBNI Hematopathology
Verified by
 Final Laboratory Report PID : 9720590

Name : Mrs YELACHURI NAVEENA Sex/Age : Female / 33

30 Years
Years Lab ID : 60634601307
Ref. By : SRF ID : Ref. ID :
Corporate : NDPL - Visit Health UHID :
Col Dt. Time : 29-Jun-2026 10:09 Recv Dt. Time : 29-Jun-2026 10:09 Sample Type : Urine
Reg Dt. Time : 29-Jun-2026 10:05 Report Released @ : 30-Jun-2026 16:41 Report Printed : 30-Jun-2026 17:30

Pathological Casts 0 /HPF 0-0.3 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Crystals
Calcium oxalate Monohydrate H 2.70 /HPF 0-1.4 p/hpf
Phase Contrast Microscopy (Sedimentation
based with AIEM)

Calcium oxalate Dihydrate 0 /HPF 0-1.4 p/hpf

Sedimentation based with AIEM (Automatic
Image Evaluation Module)

Triple phosphate 0 /HPF 0-1.4 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Uric Acid H 2.1 /HPF 0-1.4 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Bacteria H 209.5 /HPF 0-29.5 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Yeast H 157 /HPF 0-0.7 p/hpf

Phase Contrast Microscopy (Sedimentation
based with AIEM)

Amorphous Deposits 0 /HPF 0-29.5 p/hpf

Sedimentation based with AIEM (Automatic
Image Evaluation Module)

------------------ End Of Report ------------------

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh,A-Abnormal)

AUTO [Link] Bibi

MD Pathology,
MC-5972
Page 14 of 14 PDF HBNI Hematopathology
Verified by